Table 1.
Baseline characteristics
| Variable | TACE plusS-1(n = 15) | TACE monotherapy (n = 11) | P value |
|---|---|---|---|
| Gender, Male/Female (n) | 10/5 | 7/4 | 1.000 |
| Age, year (mean ± SD) | 61.7 ±11.0 | 62.1 ±11.6 | 0.925 |
| Tumor size, cm (mean ± SD) | 7.9 ±3.8 | 7.2 ±4.4 | 0.658 |
| Tumor number, median (range) | 3 (1–10) | 4 (1–8) | 0.854 |
| Cirrhosis, case number (n) | 10 | 7 | 1.000 |
| Hepatitis B, case number (n) | 10 | 8 | 1.000 |
| Hepatitis C, case number (n) | 1 | 0 | NA |
| α-fetoprotein > 400 ng/m (n) | 8 | 6 | 1.000 |
| Total bilirubin, µmol/l (mean ± SD) | 21.1 ±5.4 | 20.5 ±7.2 | 0.786 |
| Albumin, g/dl (mean ± SD) | 34.9 ±4.6 | 35.5 ±4.1 | 0.742 |
| Alanine aminotransferase, U/l (mean ± SD) | 46.8 ±21.9 | 44.6 ±17.9 | 0.781 |
| Platelets, 10ł/µl (mean ± SD) | 97.5 ±27.4 | 96.6 ±37.6 | 0.949 |
| Prothrombin time, second (mean ± SD) | 12.4 ±1.9 | 12.7 ±2.1 | 0.650 |
| Previous TACE, median (range) | 3 (1–5) | 3 (1–5) | 0.808 |
NA – not available